Cantor Fitzgerald reiterates Ideaya Biosciences stock rating

Cantor Fitzgerald reiterated its Overweight rating on Ideaya Biosciences, saying ESMO updates on partner Hengrui’s IDE849 DLL3 ADC could increase investor confidence; the firm also cited potential opportunities in neuroendocrine cancers and a possible expedited approval path. Guggenheim raised its price target to $57 from $54, while Citizens upgraded the stock to Market Outperform with a $42 target. IDE849 data updates are expected in the second half of 2026, and Ideaya plans an R&D Day on November 16 focused on its MTAP/CDKN2A and KRAS strategy.

Analysis

The actionable signal is event risk in IDEAYA (IDYA), not a read-through to Samsung. Near-term enthusiasm appears crowded: multiple bullish analyst notes and a share price near its 52-week high raise the bar for ESMO data to produce further upside. Treat the “best-in-class” and expedited-approval language as hypotheses, not established advantages; cross-trial comparisons with Zai Lab (ZLAB) and Amgen (AMGN) are not proof of superior efficacy or tolerability.

The key value inflection is whether IDE849 shows durable activity with manageable safety, especially in patients previously treated with Imdelltra. A credible signal could improve the program’s strategic value and support IDYA, while posing a longer-dated competitive risk to Amgen’s franchise. That threat is premature: trial execution, regulatory review, and any commercial launch remain substantial gates. Hengrui’s role also makes partnership economics and control of development important diligence items; clinical progress alone does not establish IDEAYA’s share of eventual value.

Over days, ESMO can drive a sharp move either way. Over 1–3 months, the November 16 R&D Day may redirect attention toward IDEAYA’s other programs, but it does not replace IDE849 evidence. Over 6–18 months, global data, Phase 3 execution, and the planned PRMT5 update matter more than analyst ratings. The contrarian risk is that favorable commentary has pulled forward expectations before the underlying data and economics are fully verifiable.

Key Decisions for Investors

• Do not chase IDYA common stock solely on analyst upgrades. For investors seeking event exposure, consider a small, defined-risk call spread rather than uncapped upside exposure; size for a substantial post-data decline and avoid holding through the readout if the risk budget cannot absorb it.
• Use ESMO as a diligence gate: verify response rate, duration, safety, patient mix, and results specifically in post-Imdelltra patients. Weak durability, meaningful toxicity, or an unclear dataset would undermine the bullish thesis even if headline response figures appear encouraging.
• Keep AMGN and ZLAB as competitive benchmarks, not automatic shorts. Reassess any relative-value trade only if IDE849 produces differentiated data and subsequent development progress; early clinical evidence alone is insufficient to establish displacement risk.
• Before underwriting long-term IDYA value, verify IDEAYA’s economic rights under the Hengrui partnership, global trial timelines, and the funding implications of Phase 3. Delays, unfavorable economics, or no improvement in the evidence would falsify the upside case.